Related Experiment Videos
Current status of viral gene therapy for brain tumours
1The University of Chicago Children's Hospital, 5841 South Maryland Ave., MC 4066, Chicago, IL 60637, USA. ngupta@peds.bsd.uchicago.edu
Abstract:
Malignant glial tumours represent the majority of primary brain tumours. Despite the use of many adjunctive treatment strategies in addition to surgery, the prospect of cure or even long-term survival is poor. In the last decade, there has been an explosion of interest in the development of delivery systems that will allow the expression of exogenous genes in the CNS. For the most part, these systems are based upon modified viruses. To date, the greatest experience has been with retroviruses, herpes simplex virus 1 (HSV), adenovirus and adeno-associated virus (AAV). This review will outline the biology of these viral vectors, modifications permitting in vivo administration and their respective advantages and disadvantages for the treatment of malignant brain tumours. The present obstacles to gene therapy strategies will also be described. To date, no convincing clinical trial has emerged that provides objective proof of the superiority of gene therapy strategies as compared to conventional treatment.
Insights
Gene therapy using viral vectors shows promise for treating malignant brain tumors, but clinical trials are needed to prove its superiority over conventional treatments.
Area of Science:
- Neuro-oncology
- Gene Therapy
- Viral Vector Technology
Background:
- Malignant glial tumors are the most common primary brain tumors with poor prognoses despite current treatments.
- Gene therapy delivery systems, primarily modified viruses, are under intense investigation for central nervous system (CNS) applications.
- Key viral vectors include retroviruses, herpes simplex virus 1 (HSV), adenovirus, and adeno-associated virus (AAV).
Purpose of the Study:
- To review the biology and modifications of viral vectors for in vivo gene delivery to the CNS.
- To discuss the advantages and disadvantages of different viral vectors for treating malignant brain tumors.
- To identify current obstacles hindering the clinical application of gene therapy for brain cancers.
Main Methods:
- Review of existing literature on viral vector biology and gene therapy applications in CNS malignancies.
- Analysis of modifications enabling in vivo administration of viral vectors.
- Comparative assessment of retroviruses, HSV, adenovirus, and AAV for brain tumor gene therapy.
Main Results:
- Viral vectors offer potential for exogenous gene expression in the CNS.
- Each viral vector type possesses unique advantages and disadvantages for brain tumor treatment.
- Significant obstacles remain in the development and clinical translation of these gene therapy strategies.
Conclusions:
- While viral vector-based gene therapy is a rapidly developing field for brain tumors, robust clinical evidence is still lacking.
- Further research and well-designed clinical trials are necessary to establish the efficacy of gene therapy compared to standard treatments.
- Overcoming current challenges is crucial for realizing the therapeutic potential of gene therapy in neuro-oncology.